Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-11-01

Clinical Trial Update: Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"

View source ↗

Summary

Clinical trial update for leuprorelin injection kit in premenopausal breast cancer; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Leuprorelin Injection Kit 22.5 mg (leuprorelin)

Snippet

Sponsor: Takeda | Conditions: Premenopausal Breast Cancer | Status: COMPLETED | Results posted: 2019-11-01